Enzyme News and Research

RSS

JAK3 pathway highlighted as leukemia target

An intriguing study published in Expert Review of Anticancer Therapy has revealed that the signaling protein JAK3 represents a viable target in the treatment of a broad range of B-lineage cancers, including acute lymphoblastic leukemia (ALL).

28 Nov 2010

Most 'worried well' groups at risk of liver disease

Growing groups of the so-called "worried well" are putting their lives at risk by shunning visits to their GP over alcoholic health related matters, according to new evidence.

25 Nov 2010

Immunity-enhancing probiotics may be the best line of defense for good health

Good bacteria, bad bacteria, billions of bacteria—sounds downright germy. But the truth is that research in gut health is germinating more insight into the role bacteria, also known as "probiotics," play in our overall health and wellness.

25 Nov 2010

E. coli host bacterium produces antibiotic erythromycin A

Researchers at Tufts University School of Engineering have reported the first successful production of the antibiotic erythromycin A, and two variations, using E. coli as the production host.

24 Nov 2010

A new treatment landscape for triple-negative breast cancer

A concerted R&D effort directed at triple-negative breast cancer patients promises new treatment options in the near future, according to latest research from independent market analyst, Datamonitor.

24 Nov 2010

On Thanksgiving Day never mind conflict with the in-laws; it's cake vs. cranberry, pie vs. wine

If you're lucky, it will all be kisses and hugs around the Thanksgiving dinner table, with friends and family near and dear gathered about, and puppies gathered around your feet waiting for table scraps.

24 Nov 2010

Plant-derived bioscavenger protects against pesticide and nerve agent organophosphate poisoning

The brain is forever chattering to itself, via electrical impulses sent along its hard-wired neuronal "Ethernet." These e-messages are translated into chemical transmissions, allowing communication across the narrow cleft separating one neuron from another or between neurons and their target cells. Of the many kinds of molecules involved in this lively chemical symposium, acetylcholine is among the most critical, performing a host of functions in the central and peripheral nervous system.

24 Nov 2010

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

Two thirds of breast cancers are ERalpha-positive, i.e., many estrogen receptors of the ERalpha- type are found in their cells. "These molecules can interact with the estrogen hormone and, thus, even lead to cancer," explains Dr. Joerg Hoheisel; molecular biologist at DKFZ. "The connection between the levels of the estrogen receptor alpha and the occurrence of breast cancer has been known for some time now.

24 Nov 2010

Verenium enters agreement with Desmet Ballestra for Purifine enzymatic degumming process

Verenium Corporation, a pioneer in the development and commercialization of high-performance enzymes solutions, today announced an agreement with Desmet Ballestra Group s.a., a leading global solutions provider in the field of engineering and delivery of installations and equipment for the edible oil and fats and biodiesel industries, to jointly market the Purifine enzymatic degumming process, which combines Verenium's Purifine PLC enzyme and Desmet Ballestra's engineering services and equipment.

23 Nov 2010

Vertex submits NDA for telaprevir for treating hepatitis C

Vertex Pharmaceuticals Incorporated announced that it has completed the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for telaprevir, Vertex's investigational treatment for people with hepatitis C.

23 Nov 2010

Rate, direction of axon growth in spinal cord can be controlled, study shows

Both the rate and direction of axon growth in the spinal cord can be controlled, according to new research by USC College's Samantha Butler and her collaborators.

23 Nov 2010

Transparent develops new medium for Cell-able array kit to maintain metabolite activity

Transparent Inc. announced that it has developed a more advanced medium for Cell-able, a human hepatocyte array kit that has the potential to reduce drug development costs and time-to-market for pharmaceutical companies. Transparent first introduced Cell-able in the United States a year ago.

22 Nov 2010

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

On November 20 at the American Society of Nephrology 43rd Annual Meeting, interim results presented from an ongoing, randomized prospective study conducted independently by James A. Tumlin, MD, at the University of Tennessee College of Medicine Chattanooga indicated that 9 of 15 patients (60%) with advanced diabetic nephropathy who are currently enrolled in the study and have completed or are still undergoing a six month course of treatment with H.P. Acthar ® Gel have exhibited a clinically significant decrease in proteinuria and achieved stabilized renal function.

22 Nov 2010

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

Cell Therapeutics, Inc. announced the preliminary results of a phase II study of paclitaxel poliglumex (OPAXIO) combined with temozolomide (TMZ) and radiotherapy (RT) in patients with newly diagnosed high-grade gliomas.

22 Nov 2010

VYTORIN reduces major vascular events in patients with chronic kidney disease

In a new investigational study of VYTORIN, the cholesterol-lowering medicine from Merck, VYTORIN 10/20 mg reduced the incidence of first major vascular events defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure by a highly statistically significant 16.1 percent compared to placebo, Study of Heart and Renal Protection study involved more than 9,000 patients who, on average, had advanced or end-stage chronic kidney disease (CKD)

22 Nov 2010

Researchers reconstitute first step of break repair in cancerous cells

What prompts normal cells to transform themselves into cancerous cells. Researchers from Texas institutions, including the UT Health Science Center San Antonio, have identified factors in the very first step of the process and reconstituted this first step in the test tube. The latter accomplishment was reported Sunday [Nov. 21] in the top-tier journal Nature Structural & Molecular Biology.

22 Nov 2010

UH physicists study workings of PGK enzyme that may cause Alzheimer's, cancer

University of Houston physicists are using complex computer simulations to illuminate the workings of a crucial protein that, when malfunctioning, may cause Alzheimer's and cancer.

20 Nov 2010

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

An old pinworm medicine is a new lead in the search for compounds that block a signaling pathway implicated in colon cancer. The findings, reported by Vanderbilt University Medical Center researchers in the November issue of Nature Chemical Biology, suggest a fresh approach for developing therapeutics that target the pathway.

20 Nov 2010

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Cough medicine could be used as way of predicting how well individual patients metabolise tamoxifen used in the treatment of their breast cancer, according to new research presented at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Berlin today

19 Nov 2010

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

New University of Georgia research, published this week in the early online edition of the journal Proceedings of the National Academy of Sciences, has found that blocking the action of an enzyme called GnT-V significantly delays the onset and spread of tumors in mice with cancer very similar to many cases of human breast cancer.

19 Nov 2010

Enzyme News and Research

JAK3 pathway highlighted as leukemia target

Most 'worried well' groups at risk of liver disease

Immunity-enhancing probiotics may be the best line of defense for good health

E. coli host bacterium produces antibiotic erythromycin A

A new treatment landscape for triple-negative breast cancer

On Thanksgiving Day never mind conflict with the in-laws; it's cake vs. cranberry, pie vs. wine

Plant-derived bioscavenger protects against pesticide and nerve agent organophosphate poisoning

Blocking miR-375 microRNA in ERalha-positive breast cancer cells slows down cancer cell growth

Verenium enters agreement with Desmet Ballestra for Purifine enzymatic degumming process

Vertex submits NDA for telaprevir for treating hepatitis C

Rate, direction of axon growth in spinal cord can be controlled, study shows

Transparent develops new medium for Cell-able array kit to maintain metabolite activity

Interim results from H.P. Acthar Gel study in patients with advanced diabetic nephropathy

Cell Therapeutics announces preliminary results of phase II OPAXIO study for high-grade gliomas

VYTORIN reduces major vascular events in patients with chronic kidney disease

Researchers reconstitute first step of break repair in cancerous cells

UH physicists study workings of PGK enzyme that may cause Alzheimer's, cancer

FDA-approved anti-parasite drug blocks Wnt signaling pathway in colon cancer

Cough suppressant syrup may predict patients metabolise tamoxifen in breast cancer treatment

Mouse study finds blocking GnT-V enzyme delays breast cancer growth

Biochemistry eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest Life Science News